Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.
Related to this article
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
No efficacy benefit was found in adding SBRT to dual checkpoint blockade, though a subset of patients responded to nivolumab plus ipilimumab.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
First-Line Ivonescimab Plus Chemotherapy Meets OS End Point in Advanced Biliary Tract Cancer
2
Five Under 5: Top Oncology Videos for the Week of 8/23
3
sNDA Submitted to FDA for Gedatolisib in PIK3CA-Mutant, HR+/HER2-Negative Advanced Breast Cancer
4
Belzutifan Plus Lenvatinib Yields Comparable HRQoL to Cabozantinib in Post–PD-(L)1 RCC
5